NFL Alumni Association and Pacira BioSciences Partner to Educate Athletes and Communities About … | Your money

TAMPA, Fla. and MOUNT LAUREL, NJ, Aug. 09, 2022 (GLOBE NEWSWIRE) — The National Football League Alumni Association (NFLA), the oldest, best-known and most respected organization for retired players in professional sports, and Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to opioid-free pain management and regenerative health solutions, today announced the launch of its partnership to increase awareness the availability and benefits of non-opioid options for managing acute and chronic pain, including post-surgical pain and knee osteoarthritis (OA).

The program aims to educate retired players, NFLA chapter presidents and staff, youth sports organizations including Play 60, Pop Warner and the Amateur Athletic Union (AAU) on the importance of options non-opioid pain management products that can reduce or eliminate the need for opioids, which may be associated with unwanted and potentially serious side effects.

The partnership will include educational opportunities at national and local NFLA chapter events, as well as national tournaments throughout the year, including the Super Bowl, Pro Bowl, Super Bowl of Golf, Red , White, & Blue Celebrity Golf Classic and the NFLA Super Bowl Pro-Am.

“I have first-hand personal knowledge of the value our partnership with Pacira BioSciences will bring to our members,” said Beasley Reese, CEO of NFL Alumni. “Pacira Biosciences products have significantly reduced the pain my wife Paula felt when she had knee replacement surgery. She used fewer dangerous narcotics and felt less pain during this difficult operation and rehabilitation. Her knee was still numb two months after a pain blocking procedure, and she was able to rehabilitate harder and faster thanks to Pacira Biosciences products. Opioids can have terrible side effects, and NFL Alumni members will use fewer dangerous drugs and have better outcomes because of this partnership.

Educational content and resources will also be shared with athletes and their families through NFLA newsletters, social media and company meetings.

“Partnering with the NFLA provides Pacira with a unique and engaging way to educate athletes at every stage of the game about the non-opioid options available to treat acute and chronic pain,” said Dave Stack, CEO and President of Pacira. BioSciences, Inc. “Our work with respected partners like the NFLA allows us to help support player safety while raising awareness of pain management options that can play a critical role in addressing the opioid crisis. “

The program will launch this fall with various events and activations ending in May 2025.

About the NFL Alumni Association Founded in 1967, the NFL Alumni Association was created to serve its retired members and their families. The main objective of the association is to engage former players through a fraternal structure supporting their ability to live better in retirement. Part of this mission is to create career opportunities, social commitments and social responsibility. Social responsibility has led to the core mission of caring for children, caring for our own, and caring for our community. The 42 chapters of the association meet in quarterly meetings to assess the well-being of members, talk about football and develop charitable initiatives to support and sustain our missions. Historically, the philanthropic and charitable efforts of chapter leaders allow the association to donate an average of $1.5 million to children’s charities in local chapter areas.

About Pacira Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue-only therapy. The company also develops innovative interventions to treat debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain and spasticity. Pacira offers three commercial-stage non-opioid therapies: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for the management post-surgical pain; ZILRETTA® (triamcinolone acetonide sustained-release injectable suspension), a sustained-release intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera°®, a new portable device to deliver immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the company’s mission to reduce excessive opioid addiction, visit

Investor Contact: Susan Mesco, (973) 451-4030 [email protected] Pacira Media Contact: Sara Marino, (973) 248-7005 [email protected] NFLA Media Contact: Emily Caniglia, (973) 587-8424 [email protected]

Copyright 2022 GlobeNewswire, Inc.

Andrew B. Reiter